Veristat buys U.K.’s Spero Oncology in European push


Yet another U.S.-based CRO is expanding into Europe with this week’s purchase of Spero Oncology by Southborough, MA’s Veristat.

Veristat, which employs more than 150 people and serves clients ranging from startups to multinationals, will grow its offerings in the European markets as well as in Australia and New Zealand through the purchase of Spero--which specializes in oncology clinical trials. U.K.-based Spero will be integrated “immediately” and begin operating under the Veristat name, according to the company's statement.

The purchase comes just over a week after Greenwich, CT’s Aptuit inked a deal for Exquiron in Switzerland to grow its presence on the continent. And before that, China’s WuXi snapped up Germany’s Crelux to maintain its push into Europe.

“Veristat’s expansion into Europe marks an important milestone in our history,” Veristat CEO Patrick Flanagan said in a statement. “The Spero team has an impressive reputation for delivering valuable guidance and insight to their clients’ clinical trials. We feel that this team is a great fit culturally and professionally and will enhance our ability to make a difference in the trials we perform on behalf of sponsors.”

With the move, Veristat brings on board Spero’s founder and managing director Theresa Bruce as its vice president of clinical operations, a role in which she’ll “provide leadership and strategic oversight” for the outfit.

Founded more than 20 years ago, Veristat’s offerings include consulting, clinical monitoring, pharmacovigilance support and data management. It focuses on oncology work and offers its services in other areas such as infectious disease, rare disease, neurology and cardiology.

Spero’s sale amount wasn’t disclosed.

- here's the release